Tumor Genomic Subtype Might Influence Level of ctDNA Shedding in NSCLC
Investigators retrospectively analyzed circulating tumor DNA (ctDNA)-based and tissue-based genomic data from 144 patients with non-small cell lung cancer (NSCLC).
Investigators retrospectively analyzed circulating tumor DNA (ctDNA)-based and tissue-based genomic data from 144 patients with non-small cell lung cancer (NSCLC).
Investigators estimated the risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) related to PARP inhibition.
Lenalidomide is typically prescribed to individuals with multiple myeloma who have received at least 1 prior therapy.
Learning from the ongoing coronavirus pandemic, ASCO released recommendations to modify policies to improve access to cancer care and research.
Patients with prostate cancer who received androgen deprivation therapy in the adjuvant setting instead of the neoadjuvant setting had better clinical outcomes.
Treatment at a radiation facility that had a high level of experience treating patients with prostate cancer was associated with better patient survival.
A CAR-T therapy that targets B-cell maturation antigen showed clinical activity in heavily pretreated patients with relapsed/refractory multiple myeloma.
Idecabtagene vicleucel showed clinical benefit and no toxicity concerns in patients with relapsed and/or refractory multiple myeloma.
Two VA medical centers were each awarded one-time $50,000 grant funding to help them enroll veterans with cancer into clinical trials.
Most study authors at the 2019 Society of Gynecologic Oncology Annual Meeting failed to disclose industry relationships, a study found.